Vaderis Therapeutics Raises $152 Million Series B And Launches Phase 3 HEROIC Study For Engasertib
By Amit Chowdhry ● Yesterday at 8:19 AM
Vaderis Therapeutics has closed an oversubscribed $152 million Series B financing and initiated its global Phase 3 HEROIC study evaluating engasertib in patients with hereditary hemorrhagic telangiectasia. The private financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors and Kalehua Capital, along with existing investors Medicxi and Droia.